Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exelixis, Inc.
Settlement in Southern District of Florida federal court includes a consolidated class action complaint against UK firm’s US businesses comprising cases in Florida, New York and California – filed in 2020 over statements the products were “clinically proven” to improve “brain performance” including focus, memory, learning, accuracy, concentration and reasoning.
The approval of Cabometyx in combination with Opdivo as a first-line treatment for RCC will power substantial growth at Exelixis into 2022.
France’s Ipsen reports a solid financial performance in 2020 but is cautious about guidance for 2021, as the mid-sized pharmaceutical company’s next rare disease candidate nears the market and it looks for early-stage assets to add to its pipeline.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
- Other Names / Subsidiaries
- X-Ceptor Therapeutics, Inc.